Superworth

4D Molecular Therapeutics revenue FDMT

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
$92M
Latest quarter, Q2 FY26
$3.8M
+25107% on a year earlier
Fiscal year 2025
$85.2M
+230195% on the year before

4D Molecular Therapeutics' revenue was $92M over the twelve months to Jun 30, 2026, up 278712% on a year earlier.

In its latest quarter, Q2 FY26, it was $3.8M, up 25107% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$85.2M+230195%
FY2024$37K−99%
FY2022$3.1M−83%
FY2021$18Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$3.8M+25107%$92M
Q1 FY26$3M+21664%$88.2M
Q4 FY25$85.1M+8508900%$85.2M
Q3 FY25$90K+2900%$120K
Q2 FY25$15K+200%$33K
Q1 FY25$14K−50%$23K
Q4 FY24$1Kn/a$37K
Q3 FY24$3K−100%n/a
Q2 FY24$5K−98%n/a
Q1 FY24$28K−91%n/a
Q3 FY23$20.2M+3941%$22M
Q2 FY23$239K+48%$2.3M

Against its peers

Companies in Biotechnology nearest 4D Molecular Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
FDMT4D Molecular Therapeutics$92M
MGTXMeiraGTx$397.5M
PLXProtalix BioTherapeutics$80.6M+30% a year
VCELVericel$306.3M+23% a year
ADMAAdma Biologics$512.3M+8% a year
Peer median$351.9M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on 4D Molecular Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.